642-52-4

Basic information

• Product Name: (-)-Montanine
• Synonyms: (6aS)-5,6a,7,8,9,11-Hexahydro-9β-methoxy-6β,11β-methano-6H-1,3-benzodioxolo[5,6-c][1]benzazepin-8α-ol;2-O-Methylpancracine;Montanine【Haemanthus】
• CAS NO: 642-52-4
• Molecular Formula: C₁₇H₁₉NO₄
• Molecular Weight: 301.33706
• Mol File: 642-52-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (-)-Montanine(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-Montanine(642-52-4)
• EPA Substance Registry System: (-)-Montanine(642-52-4)

Safety Data

• Hazardous Substances Data: 642-52-4(Hazardous Substances Data)

Usage

Description

(-)-Montanine is a naturally occurring tertiary alkaloid found in certain plant species, such as Amaryllidaceae. It possesses potential medicinal properties, including anti-tumor and anti-inflammatory effects, which make it a subject of interest in the development of new pharmaceuticals. However, its toxicity also poses a challenge in its application, necessitating further studies to fully understand its potential medicinal benefits and risks.
Used in Pharmaceutical Industry:
(-)-Montanine is used as a potential pharmaceutical candidate for its anti-tumor and anti-inflammatory effects. Its ability to target tumor cells and reduce inflammation makes it a promising substance for the development of new medications. However, due to its toxicity, careful research and development are required to ensure its safe and effective use in pharmaceutical applications.
Used in Cancer Research:
(-)-Montanine is used as a subject of interest in cancer research for its potential anti-tumor effects. Further studies are needed to explore its mechanisms of action and to determine how it can be harnessed to develop new cancer treatments while mitigating its toxic effects.
Used in Inflammation Research:
(-)-Montanine is used as a subject of interest in inflammation research for its potential anti-inflammatory properties. Research into its effects on inflammation may lead to the development of new treatments for various inflammatory conditions, provided that its toxicity can be managed effectively.

Upstream product

• 1429046-70-7 C₂₂H₂₉NO₆Si 
• 1429046-71-8 C₂₂H₃₁NO₄Si 
• 1429055-11-7 C₁₇H₁₇NO₄*ClH 
• 1429046-74-1 C₁₈H₁₉NO₅ 
• 191787-73-2 C₁₈H₂₁NO₅ 
• 139025-49-3 (+/-)-O-benzylcoccinine 
• 17680-04-5 (3,4-methylenedioxy)phenylmagnesium bromide 
• 139025-41-5 (1R*,2S*)-2-<3',4'-(methylenedioxy)benzoyl>-4-cyclohexenecarboxylic acid 
• 139039-77-3 (+/-)-2,3-cis-3-benzyloxy-2-hydroxy-4a,11a-cis-11,11a-syn-5,11-methano-8,9-methylenedioxymorphanthrine 
• 139025-47-1 5,11-methanomorphanthridin-2-one 
• 139025-46-0 2,3-Benzylidenedioxy-8,9-methylenedioxy-5,11-methanomorphanthridine 
• 139025-48-2 C₂₃H₂₁NO₄ 
• 139025-42-6 (1R*,2S*)-2-<3',4'-(methylenedioxy)benzoyl>-4-cyclohexenyl-N-tosylamide 
• 144609-79-0 (2S*,3R*,4aR*,11S*,11aR*)-2,3-dihydroxy-11-(hydroxymethyl)-8,9-(methylenedioxy)-5-tosylmorphanthridine 

Downstream Products

• 606-51-9 (-)-manthine 
• 21416-14-8 pancracine 

Relevant articles and documents

-

-

Total synthesis of montanine-type Amarylliidaceae alkaloids, which possess a 5,11-methanomorphanthridine ring system, through cyclization with sodium bis(2-methoxyethoxy)aluminum hydride: The first stereoselective total syntheses of (±)-montanine, (±)-coc

-